Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma.

× No keyword cloud information.

5 in total

1. Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).

Authors: M Donini; S Buti; S Lazzarelli; R Bozzetti; L Rivoltini; C Camisaschi; C Castelli; A Bearz; C Simonelli; G Lo Re; R Mattioli; C Caminiti; R Passalacqua
Journal: Target Oncol Date: 2014-09-19 Impact factor: 4.493

2. Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.

Authors: Saby George; Robert Dreicer; Jessie J L Au; Tong Shen; Brian I Rini; Susan Roman; Matthew M Cooney; Tarek Mekhail; Paul Elson; Guillaume M Wientjes; Ram Ganapathi; Ronald M Bukowski
Journal: Clin Genitourin Cancer Date: 2008-09 Impact factor: 2.872

3. A phase II trial of pemetrexed in patients with metastatic renal cancer.

Authors: R Thödtmann; T Sauter; S Weinknecht; L Weissbach; J Blatter; U Ohnmacht; A- R Hanauske
Journal: Invest New Drugs Date: 2003-08 Impact factor: 3.850

4. Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer.

Authors: Robert J Amato; Cherie Perez; Lance Pagliaro
Journal: Invest New Drugs Date: 2002-11 Impact factor: 3.850

5. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.

Authors: Amy C Peterson; Helena Harlin; Theodore Karrison; Nicholas J Vogelzang; James A Knost; John W Kugler; Eric Lester; Everett Vokes; Thomas F Gajewski; Walter M Stadler
Journal: Invest New Drugs Date: 2006-03 Impact factor: 3.850

5 in total